Effect of heparin and contrast medium on platelet function during routine cardiac catheterisation.
Platelet function was studied during coronary angiography of patients complaining of chest pain. The following changes occurred 5 min after injecting 100 IU.kg-1 body weight of a conventional high molecular weight heparin: (a) a significant fall in platelet count; (b) a significant enhancement of platelet aggregation in platelet rich plasma (turbidometric technique) and in whole blood (platelet aggregation technique); and (c) significantly enhanced release of platelet thromboxane A2, a vasoconstrictor. These changes tended to reverse towards baseline values 5 min after injecting a contrast medium (Conray 420), which was found to inhibit platelet aggregation. Thus heparinisation with a high molecular weight heparin seems to cause pronounced activation of platelets in patients undergoing coronary angiography, and this may contribute to the pathogenesis of cardiac ischaemia that may occur during this procedure. Since coronary artery bypass surgery in similar patients involves the use of heparin at much higher doses without the concomitant use of an antiaggregatory contrast medium, it is possible that platelet hyperaggregability may contribute to the well documented ischaemic brain injury associated with this form of surgery. Furthermore, the use of high molecular weight heparin after successful coronary angioplasty or thrombosis may influence the incidence of reocclusion. These findings therefore suggest that low molecular weight heparinoids should be evaluated in these situations since these anticoagulants are only weak activators of platelet aggregation.
Greenbaum
R A
RA
Department of Cardiology, Royal Free Hospital, London.
Barradas
M A
MA
Mikhailidis
D P
DP
Jeremy
J Y
JY
Evans
T R
TR
Dandona
P
P
D000328:Adult; D000368:Aged; D001792:Blood Platelets / Q000187:drug effects* / Q000503:physiopathology; D006328:Cardiac Catheterization; D003287:Contrast Media / Q000494:pharmacology*; D003327:Coronary Disease / Q000097:blood*; D005260:Female; D006493:Heparin / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation; D010976:Platelet Count
D003287:Contrast Media; D006493:Heparin